Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 243 of 1,261

  1. US 11426385

    Methods of improving cancer chemotherapy

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  2. US 11426409

    Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers

    The Regents of the University of Colorado · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  3. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  4. US 11426461

    Methods for preventing dengue and hepatitis A

    Takeda Vaccines, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  5. US 11426366

    Compositions and methods for treating motor disorders

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  6. US 11427838

    Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders

    Vertex Pharmaceuticals Incorporated · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  7. US 11427588

    Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

    The Regents of the University of California · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  8. US 11427646

    Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

    B CELL DESIGN · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  9. US 11427605

    Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

    Takeda Pharmaceutical Company Limited · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  10. US 11427816

    Cancer treatment through RLIP76 partial depletion

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  11. US 11427581

    JAK inhibitor and use thereof

    ZHUHAI UNITED LABORATORIES CO., LTD. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  12. US 11427820

    Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

    BIOMARIN TECHNOLOGIES B.V. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  13. US 11427822

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  14. US 11427644

    Dual antigen-induced bipartite functional complementation

    Julius-Maximilians-Universitat Wurzburg · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  15. US 11426486

    Chitosan-containing formulations

    PRIMEX EHF · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  16. US 11426373

    Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

    Jazz Pharmaceuticals Ireland Limited · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  17. US 11427571

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    DENALI THERAPEUTICS INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  18. US 11427823

    Targeted compositions

    ARBUTUS BIOPHARMA CORPORATION · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  19. US 11426418

    Injectable long-acting semi-solid gel formulations

    MIRA PHARMA CORPORATION · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  20. US 11426414

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  21. US 11426446

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  22. US 11426420

    Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  23. US 11426464

    Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  24. US 11427540

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.